|
|
|
|
Azithromycin Alters Macrophage Phenotype and Pulmonary Compartmentalization during Pseudomonas Pneumonia [Article]
Azithromycin Alters Macrophage Phenotype and Pulmonary Compartmentalization during Pseudomonas Pneumonia David J.Feola*, Beth A. Garvy, Theodore J. Cory, Susan E. Birket, Heather Hoy, Don Hayes Jr., and Brian S. Murphy Departments of Pharmacy...
|
|
|
Enhancement of Biofilm Formation by Subinhibitory Macrolides in icaADBC-Positive and -Negative Clinical Isolates of Staphylococcus epidermidis [Article]
Biofilm formation in Staphylococcus epidermidis is mediated by icaADBC -dependent and -independent pathways.Subinhibitory erythromycin, azithromycin and clarithromycin markedly enhanced, in vitro in a dose-dependent manner, biofilm formation of 20% (21...
|
|
|
News and FDA Updates for Impax (NASDAQ:IPXL), Insmed (Nasdaq:INSM), Inspire (NASDAQ:ISPH)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials...
|
|
|
New Mutation in 23S rRNA Gene Associated with High Level of Azithromycin Resistance in Neisseria gonorrhoeae
Mutation in 23S rRNA Gene Associated with High Level of Azithromycin Resistance...Galarza et al. Antimicrob. Agents 54: 1652-1653 To view this item, select one of the options below: Sign In User Name Password your user name or password? Purchase...
|
|
|
Inspire Announces Results From AZASITE Phase 2 Blepharitis Trials and Plans to Continue ...
Inspire Pharmaceuticals announced the results from two Phase 2 clinical trials with AZASITE (azithromycin ophthalmic solution) 1% for the treatment of blepharitis.Inspire will conduct additional clinical work to continue pursuing a potential indication...
|
|
|
Antibiotic prescription patterns in hospitalized patients with nursing home-acquired pneumonia
Considerable research has increased our understanding of antibiotic prescribing practices in hospital settings when it comes to nosocomial pneumonia.Much less is known about the antibiotic prescribing patterns for hospitalized non-critically ill patients...
|
|
|
Despite failed primary endpoints, AzaSite shows promise for treating blepharitis in clinical program
DURHAM, N.C.- AzaSite was well-tolerated and statistically significantly improved the signs and symptoms of blepharitis in a phase 2 clinical program, according to a press release from Inspire Pharmaceuticals. Designed to assess the efficacy of different...
|
|
|
Azithromycin Alters Macrophage Phenotype and Pulmonary Compartmentalization during Pseudomonas Pneumonia
David J.Feola*, Beth A. Garvy, Theodore J. Cory, Susan E. Birket, Heather Hoy, Don Hayes Jr., and Brian S. Murphy Departments of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, Kentucky 40536; Departments of...
|
|
|
Enhancement of Biofilm Formation by Subinhibitory Macrolides in icaADBC-Positive and -Negative Clinical Isolat
Antimicrob.Agents Chemother. doi:10.1128/AAC.01565-09 Copyright (c) 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved. Qian Wang, Feng-Jun Sun, Yao Liu, Li-Rong Xiong, Lin-Li Xie, and Pei-Yuan Xia*...
|
|
|
Inspire Pharmaceuticals reports results of two AZASITE Phase 2 clinical trials for blepharitis
Inspire Pharmaceuticals, Inc.(NASDAQ: ISPH) announced today the results from two Phase 2 clinical trials with AZASITE (azithromycin ophthalmic solution) 1% for the treatment of blepharitis. Inspire will conduct additional clinical work to continue...
|
|
|
Inspire Announces Results From Azasite Phase 2 Blepharitis Trials and Plans to Continue Clinical Development i
- Inspire Pharmaceuticals, Inc.(NASDAQ: ISPH) announced today the results from two Phase 2 clinical trials with AZASITE (azithromycin ophthalmic solution) 1% for the treatment of blepharitis. Inspire will conduct additional clinical work to continue...
|
|
|
Inspire Announces Results From AZASITE Phase 2 Blepharitis Trials and Plans to Continue Clinical Development i
DURHAM, N.C.(BUSINESS WIRE) Inspire Pharmaceuticals, Inc.(NASDAQ: ISPH) announced today the results from two Phase 2 clinical trials with AZASITE (azithromycin ophthalmic solution) 1% for the treatment of blepharitis. Inspire will conduct additional...
|
|
|
Inspire Announces Results From AZASITE Phase 2 Blepharitis Trials and Plans to Continue Clinical Development in Anterior and Posterior Blepharitis
DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc.(NASDAQ: ISPH) announced today the results from two Phase 2 clinical trials with AZASITE (azithromycin ophthalmic solution) 1% for the treatment of blepharitis. Inspire will conduct...
|
|
|
Inspire Announces Results From AZASITE Phase 2 Blepharitis Trials and Plans to Continue Clinical Development in Anterior and Posterior Blepharitis
Companies mentioned in this article: Inspire Pharmaceuticals, Inc.DURHAM, N.C. -- (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the results from two Phase 2 clinical trials with AZASITE (azithromycin ophthalmic...
|
|
|
Inspire Announces Results From AZASITE Phase 2 Blepharitis Trials and Plans to Continue Clinical Development
Inspire Pharmaceuticals, Inc.(NASDAQ: ISPH) announced today the results from two Phase 2 clinical trials with AZASITE (azithromycin ophthalmic solution) 1% for the treatment of blepharitis. Inspire will conduct additional clinical work to continue...
|
|
|
Inspire Announces Results From AZASITE Phase 2 Blepharitis Trials and Plans to Continue Clinical Development in Anterior and Posterior Blepharitis
Clinical Trials Update Breaking News News source: Business Wire Inspire Pharmaceuticals, Inc.(NASDAQ: ISPH) announced today the results from two Phase 2 clinical trials with AZASITE (azithromycin ophthalmic solution) 1% for the treatment of blepharitis...
|
|
|
Inspire Pharma (ISPH) Updates on AZASITE Phase 2
Inspire Pharmaceuticals, Inc.(NASDAQ: ISPH) announced today the results from two Phase 2 clinical trials with AZASITE (azithromycin ophthalmic solution) 1% for the treatment of blepharitis. Inspire will conduct additional clinical work to continue...
|
|
|
InSite Vision narrows loss for fourth quarter, full year
Submit a Comment ALAMEDA, Calif.- InSite Vision reported a net loss of $2 million, or $0.02 per share, for the fourth quarter, compared with a net loss of $8.6 million, or $0.09 per share, for the fourth quarter of 2008, the company announced in a press...
|
|
|
An MD and DVM Q&A with Dr. Breitschwerdt
In the cases you described, is there evidence that treating with antibiotics improved any of the nonspecific symptoms in the affected people?An authoritative review in the human literature published two or three years ago on how to treat Bartonella species...
Thomson Veterinary Healthcare Communications:
Mar 11 2010 6:20AM
Matching: azithromycin
|
Find similar documents
|
|
|
|
Cempra Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new market report released
Refer to a friend 2010-03-10 18:47:12 - Cempra Pharmaceuticals, Inc.- Pharmaceuticals & Healthcare - Deals and Alliances Profile - a new market research report on companiesandmarkets.com Cempra Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare -...
|
|
|
InSite Vision Reports Full Year and Fourth Quarter 2009 Financial Results
ALAMEDA, Calif.-- (BUSINESS WIRE) -- (OTCBB: INSV) today reported financial results for the full year and fourth quarter ended December 31, 2009.2009 was a year of steady performance by InSite Vision in which we executed against our strategic objectives,...
|
|
|
InSite Vision Reports Full Year and Fourth Quarter 2009 Financial Results
AzaSite Revenues Up 91 Percent Over 2008 ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV - News) today reported financial results for the full year and fourth quarter ended December 31, 2009.2009 was a year of steady performance by...
|
|
|
InSite Vision Reports Full Year and Fourth Quarter 2009 Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV.OB) today reported financial results for the full year and fourth quarter ended December 31, 2009.2009 was a year of steady performance by InSite Vision in which we executed against...
|
|
|
InSite Vision Reports Full Year and Fourth Quarter 2009 Financial Results
(BUSINESS WIRE) ----InSite Vision Incorporated (OTCBB: INSV) today reported financial results for the full year and fourth quarter ended December 31, 2009."2009 was a year of steady performance by InSite Vision in which we executed against our strategic...
|
|
|
InSite Vision Reports Full Year and Fourth Quarter 2009 Financial Results
"2009 was a year of steady performance by InSite Vision in which we executed against our strategic objectives," said Louis Drapeau, InSite Vision's Chief Executive Officer."We begin 2010 in a solid cash position, having successfully conserved our financial...
|
